Literature DB >> 20472200

Optic nerve tumor in tuberous sclerosis complex is not responsive to sirolimus.

Steven P Sparagana1, David C Wilkes, Catherine E Thompson, Daniel C Bowers.   

Abstract

A 12-year-old girl with clinically established tuberous sclerosis complex, and without signs of neurofibromatosis type 1, developed a right retro-ocular optic nerve tumor. After rapid growth for 1 year after its discovery, the optic nerve tumor demonstrated modest progression. The patient received the mammalian target of rapamycin inhibitor, sirolimus, for recurrent subependymal giant cell brain tumors. Although her left ventricular subependymal giant cell tumor demonstrated a 49% reduction in volume, the optic nerve tumor did not respond, and even underwent slight (6%) growth during the 16-month treatment. The quality of this child's vision has remained normal in both eyes, and she is otherwise asymptomatic with regard to the optic nerve tumor. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20472200     DOI: 10.1016/j.pediatrneurol.2010.01.016

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  5 in total

1.  Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.

Authors:  Sutapa Banerjee; Scott M Gianino; Feng Gao; Uwe Christians; David H Gutmann
Journal:  Mol Cancer Ther       Date:  2011-01-07       Impact factor: 6.261

Review 2.  Rapamycin and rapalogs for tuberous sclerosis complex.

Authors:  Teguh H Sasongko; Nur Farrah Dila Ismail; Zamh Zabidi-Hussin
Journal:  Cochrane Database Syst Rev       Date:  2016-07-13

3.  Efficacy and safety of a mammalian target of rapamycin inhibitor in pediatric patients with tuberous sclerosis complex: A systematic review and meta-analysis.

Authors:  Guang Yang; Lu Yang; Xiaofan Yang; Xiuyu Shi; Jing Wang; Yujie Liu; Jun Ju; Liping Zou
Journal:  Exp Ther Med       Date:  2014-11-27       Impact factor: 2.447

Review 4.  Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis.

Authors:  Min Li; Ying Zhou; Chaoyang Chen; Ting Yang; Shuang Zhou; Shuqing Chen; Ye Wu; Yimin Cui
Journal:  Orphanet J Rare Dis       Date:  2019-02-13       Impact factor: 4.123

Review 5.  Rapamycin and its analogues (rapalogs) for Tuberous Sclerosis Complex-associated tumors: a systematic review on non-randomized studies using meta-analysis.

Authors:  Teguh Haryo Sasongko; Nur Farrah Dila Ismail; Nik Mohamad Ariff Nik Abdul Malik; Z A M H Zabidi-Hussin
Journal:  Orphanet J Rare Dis       Date:  2015-08-12       Impact factor: 4.123

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.